The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results for HS-410 Vaccine in Non-Muscle Invasive Bladder Cancer

Gary Steinberg, MD
Published Online:3:34 PM, Mon May 22, 2017

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.